AFP and neoplasm: Treatment with JPHYD yielded significant OS advantages for females, patients ≥ 60 years, and patients with BCLC A, single tumor, maximum tumor diameter ≤ 8 cm, without MVI, AFP < 400, HBV DNA ≤ 1,000, ICG ≤ 10%, or Child-Pugh A grade disease (Figure 6A).